Subjects will be randomized in a 2:1 fashion to receive up to 4 cycles of oral cladribine or matching placebo in combination with IFN-beta therapy. Subjects who complete the double-blind portion of the study will be invited to participate in an open-label extension phase of matching study design. Total participation is 96 weeks in double blind period, and up to 48 weeks in open label extension phase.